Timeline of COVID-19 Vaccines and Treatment
2020
October 22 FDA issues Emergency use Authorization (EUA) for Remdesivir in the treatment of patients hospitalized with covid-10 1)
November 16 Moderna announces that the interim results of their Covid-19 vaccine candidate Phase III clinical trial have met their primary efficacy endpoint (94.5% (p <0.0001)). 95 participants contracted Covid-19 out of 30,000 participants. 2)
November 18 Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints. 95% effective against COVID-19 beginning 28 days after the first dose. 3)
December 2 Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19. The Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2).4)
December 11 Pfizer receives an Emergency Use Authorization in the USA for it's Covid-19 vaccine. 5)
December 18 Moderna receives an Emergency Use Authorization in the USA for it's Covid-19 vaccine. 6)
2021
December 09 US FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Booster Dose to 16- and 17-Year-Olds.7)
October 29 US FDA Authorizes COVID-19 Vaccine in Children 5 through 11. 8)
September 22 US FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Those Older than 65 and those at High Risk for Sever Covid-19.9)
August 12 US FDA Authorizes Booster Dose for Immunocompromised People10)
May 10 US FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents age 12-15.11)
April 23 USA FDA and CDC Lift the Safety Pause on the Johnson & Johnson (Janssen) COVID-19 Vaccine.12)
April 13 U.S. CDC and FDA recommend a pause on the Johnson & Johnson (Janssen) vaccine due to 6 cases cerebral venous sinus thrombosis (CVST).13)
February 27 US FDA issues an emergency use authorization (EUA) for the Janssen COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older. 14)
February 9 FDA issued an EUA for emergency use of bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. 15)
2022
January 3 FDA expands Pfizer-BioNTech COVID-19 Vaccine EUA to include the use of a single booster dose in children 12 through 15 years of age; shorten the time between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 Vaccine and a booster dose to at least five months, and allow for a third primary series dose for certain immunocompromised children 5 through 11 years of age.16)
January 21 FDA expands indication for Remdesivir to non-hospitalized adults with Covid-19 17)
April 25 FDA approves Remdesivir for treatment of pediatric patients under 12 years of age with Covid-19 18)
July 13 FDA issues EUA for the Novavax vaccine in people aged 18 and over 19)